The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients
This trial is active, not recruiting.
|Treatment||tenofovir disoproxil fumarate|
|Trial identifier||NCT00007436, 283F, GS-99-910|
The purpose of this study is to evaluate the safety of tenofovir disoproxil fumarate (tenofovir DF) in combination with other anti-HIV drugs in patients who have participated in other tenofovir DF studies (GS-98-902 or GS-99-907), are able to tolerate the drug at different doses, and may benefit from having tenofovir DF treatment.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Berkeley, CA||East Bay AIDS Ctr||no longer recruiting|
|Los Angeles, CA||Tower ID Med Associates||no longer recruiting|
|San Francisco, CA||Pacific Horizons Med Group||no longer recruiting|
|Torrance, CA||Harbor - UCLA Med Ctr||no longer recruiting|
|Denver, CO||Univ of Colorado / Health Science Ctr||no longer recruiting|
|Washington, DC||Physicans Home Service||no longer recruiting|
|Miami, FL||Steinhart Medical Associates||no longer recruiting|
|Vero Beach, FL||Dr Gerald Pierone Jr||no longer recruiting|
|Chicago, IL||Northstar Med Clinic||no longer recruiting|
|Brookline, MA||CRI New England||no longer recruiting|
|Minneapolis, MN||Univ of Minnesota||no longer recruiting|
|Rochester, NY||Univ of Rochester Med Ctr||no longer recruiting|
|Portland, OR||Research & Education Group||no longer recruiting|
|Hershey, PA||Hershey Med Ctr||no longer recruiting|
|Pittsburgh, PA||Anderson Clinical Research||no longer recruiting|
|Providence, RI||Roger Williams Med Ctr||no longer recruiting|
|Dallas, TX||Southwest Infectious Diseases Associates||no longer recruiting|
|Houston, TX||Thomas Street Clinic||no longer recruiting|
|Tacoma, WA||Dr Philip C Craven||no longer recruiting|
|Endpoint classification||safety study|
Male or female participants of any age.
Inclusion Criteria Patients may be eligible for this study if they: - Have completed another study on tenofovir DF without toxicity. - Are willing to use intrauterine or effective barrier methods of birth control, both men and women, during the study and for 30 days following tenofovir DF treatment. Exclusion Criteria Patients will not be eligible for this study if they: - Are taking drugs that may damage the kidney (nephrotoxic) including aminoglycoside antibiotics, amphotericin B, cidofovir, cisplatin, foscarnet, IV pentamidine, vancomycin, and oral or IV ganciclovir. - Are taking agents that affect kidney function, such as probenecid. - Are receiving systemic chemotherapy. - Are taking systemic corticosteroids. - Are taking experimental drugs except those that are approved by Gilead. - Are currently participating in the GS-99-908 or GS-00-912 (expanded access) studies. - Are pregnant or breast-feeding.
|Official title||A Phase 3, Open-Label, Multicenter Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients|
|Description||Patients take tenofovir DF in combination with other antiretrovirals.|
Call for more information